FDA is recruiting sponsors of potential OTC naloxone applications and reports that interest is high, although concerns over pricing and the absence of physician-patient communication about using the product could be impediments to a switch.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?